When did ADMA Biologics report Q1 2025 earnings?

ADMA Biologics (ADMA) reported Q1 2025 earnings on May 7, 2025 after market close.

What were ADMA Biologics's Q1 2025 revenue and EPS?

ADMA Biologics reported revenue of $114.8M and eps of $0.14 for Q1 2025.

Did ADMA Biologics beat estimates in Q1 2025?

Revenue missed the consensus estimate of $121.8M by $7.0M. EPS missed the consensus estimate of $0.16 by $0.02.

How did ADMA Biologics's Q1 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 40.2% from $81.9M a year earlier and eps grew 75.0% from $0.08.

Where can I find ADMA Biologics's Q1 2025 SEC filings?

You can read the 10-Q periodic report (0001140361-25-017747) directly on SEC EDGAR. The filing index links above go to sec.gov.

ADMA Biologics ADMA Q1 2025 earnings

Reported May 7, 2025 · After market close

Revenue$114.8MMiss by $7.0M

EPS$0.14Miss by $0.02

Revenue estimate$121.8M

EPS estimate$0.16

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$125.3M

EPS estimate$0.16

Financials

Q1 2025

Income statement

See full

Revenue$114.8M+40.2%

Gross profit$61.1M+56.2%

Operating income$34.9M+59.9%

Net income$26.9M+51.1%

EPS (diluted)$0.11+37.5%

Balance sheet

See full

Cash & equivalents$71.6M+58.0%

Total debt$9.5M-10.3%

Total equity$373.4M+143%

Total assets$510.6M+45.5%

Cash flow

See full

Operating cash flow-$19.7M-787%

CapEx$4.7M+100%

Free cash flow-$24.4M-434%

Valuation & ratios

Valuation

as of 03/31/25

See full

Market cap$4.71B+213%

Enterprise value$4.65B+216%

P/E22.8×—

P/S10.3×+4.9×

Profitability

See full

Gross margin52.6%+13.2pp

Operating margin33.1%+17.5pp

Net margin45%+43.8pp

FCF margin19.7%+14.0pp

Returns & leverage

See full

Return on equity78.5%+76.2pp

Debt / equity0×0.0×

Current ratio6.6×+1.4×

Segments

By product

See full

ASCENIV$76.3M+27.4%

BIVIGAM$33.5M—

Intermediates And Other$3.9M—

By segment

See full

ADMA Bio Manufacturing$113.7M+41.9%

Plasma Collection Centers$1.1M-39.2%

By geography

See full

US$110.7M—

Versus estimates

Revenue

Q1 2026$114.5MMiss by $25.5M Q4 2025$139.2MMiss by $437.0K Q3 2025$134.2MMiss by $5.6M Q2 2025$122.0MMiss by $8.3M

Q1 2025$114.8MMiss by $7.0M

Q4 2024$117.5MBeat by $8.9M

Diluted EPS

Q1 2026$0.19Miss by $0.00 Q4 2025$0.20Beat by $0.02 Q3 2025$0.16In line Q2 2025$0.15Beat by $0.01

Q1 2025$0.14Miss by $0.02

Q4 2024$0.14Miss by $0.01

Ask the moment ADMA Biologics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did ADMA Biologics report Q1 2025 earnings?: ADMA Biologics (ADMA) reported Q1 2025 earnings on May 7, 2025 after market close.
What were ADMA Biologics's Q1 2025 revenue and EPS?: ADMA Biologics reported revenue of $114.8M and eps of $0.14 for Q1 2025.
Did ADMA Biologics beat estimates in Q1 2025?: Revenue missed the consensus estimate of $121.8M by $7.0M. EPS missed the consensus estimate of $0.16 by $0.02.
How did ADMA Biologics's Q1 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 40.2% from $81.9M a year earlier and eps grew 75.0% from $0.08.
Where can I find ADMA Biologics's Q1 2025 SEC filings?: You can read the 10-Q periodic report (0001140361-25-017747) directly on SEC EDGAR. The filing index links above go to sec.gov.